Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
AIDS (London, England)|December 17, 2009
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunctionEsteban Martínez, María Larrousse, Daniel Podzamczer, et al.
The Journal of Infectious Diseases|February 25, 2003
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapineElena Ferrer, Daniel Podzamczer, Mireia Arnedo, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2012
Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimenJoaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.
AIDS Research and Human Retroviruses|August 2, 2008
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot studyElena Ferrer, Jose Maria Gatell, Pochita Sanchez, et al.
The Journal of Antimicrobial Chemotherapy|January 14, 2014
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study GroupAdrian Curran, Polyana Monteiro, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|September 6, 2016
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different componentsJosep M Llibre, Elisa de Lazzari, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2009
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe, Barbara A da Silva, Daniel E Cohen, et al.
AIDS (London, England)|November 25, 2011
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran, Esteban Martinez, Maria Saumoy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2022
Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir AlafenamideSofía Scévola, Arkaitz Imaz, Mackenzie L Cottrell, et al.
Antiviral Therapy|June 21, 2011
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovirMaria Saumoy, Jordi Ordoñez-Llanos, Esteban Martínez, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
AIDS (London, England)|December 17, 2009
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunctionEsteban Martínez, María Larrousse, Daniel Podzamczer, et al.
The Journal of Infectious Diseases|February 25, 2003
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapineElena Ferrer, Daniel Podzamczer, Mireia Arnedo, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2012
Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimenJoaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.
AIDS Research and Human Retroviruses|August 2, 2008
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot studyElena Ferrer, Jose Maria Gatell, Pochita Sanchez, et al.
The Journal of Antimicrobial Chemotherapy|January 14, 2014
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study GroupAdrian Curran, Polyana Monteiro, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|September 6, 2016
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different componentsJosep M Llibre, Elisa de Lazzari, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2009
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe, Barbara A da Silva, Daniel E Cohen, et al.
AIDS (London, England)|November 25, 2011
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran, Esteban Martinez, Maria Saumoy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2022
Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir AlafenamideSofía Scévola, Arkaitz Imaz, Mackenzie L Cottrell, et al.
Antiviral Therapy|June 21, 2011
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovirMaria Saumoy, Jordi Ordoñez-Llanos, Esteban Martínez, et al.
Pageof 19